Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features
Julien Caldéraro, Benoı̂t Rousseau, Giuliana Amaddeo, et al.
Hepatology (2016) Vol. 64, Iss. 6, pp. 2038-2046
Open Access | Times Cited: 399

Showing 1-25 of 399 citing articles:

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn, Shukui Qin, Masafumi Ikeda, et al.
New England Journal of Medicine (2020) Vol. 382, Iss. 20, pp. 1894-1905
Open Access | Times Cited: 5325
Immunotherapies for hepatocellular carcinoma
Josep M. Llovet, Florian Castet, Mathias Heikenwälder, et al.
Nature Reviews Clinical Oncology (2021) Vol. 19, Iss. 3, pp. 151-172
Closed Access | Times Cited: 1164
Advances in immunotherapy for hepatocellular carcinoma
Bruno Sangro, Pablo Sarobe, Sandra Hervás‐Stubbs, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 8, pp. 525-543
Open Access | Times Cited: 931
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Natascha Roehlen, Émilie Crouchet, Thomas F. Baumert
Cells (2020) Vol. 9, Iss. 4, pp. 875-875
Open Access | Times Cited: 851
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Daniela Sia, Yang Jiao, Iris Martinez-Quetglas, et al.
Gastroenterology (2017) Vol. 153, Iss. 3, pp. 812-826
Open Access | Times Cited: 760
Molecular and histological correlations in liver cancer
Julien Caldéraro, Marianne Ziol, Valérie Paradis, et al.
Journal of Hepatology (2019) Vol. 71, Iss. 3, pp. 616-630
Open Access | Times Cited: 433
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
Ann‐Lii Cheng, Chiun Hsu, Stephen L. Chan, et al.
Journal of Hepatology (2020) Vol. 72, Iss. 2, pp. 307-319
Open Access | Times Cited: 430
Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification
Yutaka Kurebayashi, Hidenori Ojima, Hanako Tsujikawa, et al.
Hepatology (2018) Vol. 68, Iss. 3, pp. 1025-1041
Open Access | Times Cited: 367
Dual Programmed Death Receptor‐1 and Vascular Endothelial Growth Factor Receptor‐2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma
Kohei Shigeta, Meenal Datta, Tai Hato, et al.
Hepatology (2019) Vol. 71, Iss. 4, pp. 1247-1261
Open Access | Times Cited: 356
Delivery of nitric oxide with a nanocarrier promotes tumour vessel normalization and potentiates anti-cancer therapies
Yun‐Chieh Sung, Pei-Ru Jin, Li‐An Chu, et al.
Nature Nanotechnology (2019) Vol. 14, Iss. 12, pp. 1160-1169
Closed Access | Times Cited: 356
Immune checkpoint therapy in liver cancer
Feng Xu, Tianqiang Jin, Yuwen Zhu, et al.
Journal of Experimental & Clinical Cancer Research (2018) Vol. 37, Iss. 1
Open Access | Times Cited: 340
Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade
Ying Zhu, Jing Yang, Da Xu, et al.
Gut (2019) Vol. 68, Iss. 9, pp. 1653-1666
Closed Access | Times Cited: 328
Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma
Julien Caldéraro, Florent Petitprez, Étienne Becht, et al.
Journal of Hepatology (2018) Vol. 70, Iss. 1, pp. 58-65
Closed Access | Times Cited: 324
PD-L1
Anthousa Kythreotou, Abdul Siddique, Francesco Mauri, et al.
Journal of Clinical Pathology (2017) Vol. 71, Iss. 3, pp. 189-194
Open Access | Times Cited: 268
Association Between Expression Level of PD1 by Tumor-Infiltrating CD8+ T Cells and Features of Hepatocellular Carcinoma
Hyung‐Don Kim, Gi‐Won Song, Seongyeol Park, et al.
Gastroenterology (2018) Vol. 155, Iss. 6, pp. 1936-1950.e17
Closed Access | Times Cited: 234
Immunotherapy for hepatocellular carcinoma
Zongyi Yin, Xiaowu Li
Cancer Letters (2019) Vol. 470, pp. 8-17
Closed Access | Times Cited: 217
Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes
Mercedes Iñarrairaegui, Ignacio Melero, Bruno Sangro
Clinical Cancer Research (2017) Vol. 24, Iss. 7, pp. 1518-1524
Open Access | Times Cited: 216
IMbrave 050: A Phase III Trial of Atezolizumab Plus Bevacizumab in High-Risk Hepatocellular Carcinoma after Curative Resection or Ablation
Stephen P. Hack, Jessica Spahn, Minshan Chen, et al.
Future Oncology (2020) Vol. 16, Iss. 15, pp. 975-989
Open Access | Times Cited: 182
Macrophage-derived CCL5 facilitates immune escape of colorectal cancer cells via the p65/STAT3-CSN5-PD-L1 pathway
Chao Liu, Zhaoying Yao, Jianing Wang, et al.
Cell Death and Differentiation (2019) Vol. 27, Iss. 6, pp. 1765-1781
Open Access | Times Cited: 172
MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1
Hui Li, Chia‐Wei Li, Xiaoqiang Li, et al.
Gastroenterology (2019) Vol. 156, Iss. 6, pp. 1849-1861.e13
Open Access | Times Cited: 162
The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications
Jiajie Hou, Haiyan Zhang, Beicheng Sun, et al.
Journal of Hepatology (2019) Vol. 72, Iss. 1, pp. 167-182
Open Access | Times Cited: 154
M1 Macrophages Induce PD-L1 Expression in Hepatocellular Carcinoma Cells Through IL-1β Signaling
Zhaoyun Zong, Jiahuan Zou, Rudi Mao, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 151
Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions
Marc Hilmi, Cindy Neuzillet, Julien Caldéraro, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 147
GOLM1 exacerbates CD8+ T cell suppression in hepatocellular carcinoma by promoting exosomal PD-L1 transport into tumor-associated macrophages
Jinhong Chen, Zhifei Lin, Lu Liu, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 119
IL‐1β‐Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Up‐regulating Programmed Death Ligand 1 and Colony‐Stimulating Factor 1
Qin He, Mei Liu, Wenjie Huang, et al.
Hepatology (2021) Vol. 74, Iss. 6, pp. 3174-3193
Closed Access | Times Cited: 117
Page 1 - Next Page

Scroll to top